Two molecular biomarker validation programmes in Solid Oncology are currently being developed.
IntegraGen has acquired an exclusive option from INSERM-transfer for the license to use the patent originating from INSERM covering characterisation of CHCs by analysis of their molecular signature. The validation programme initiated by IntegraGen must result in a test allowing transition to clinical use of this CHC signature and its objective is to propose a diagnostics protocol making it possible to classify benign and malignant hepatocellular tumours according to their diversity and the prognosis of patients.
Based on a programme conducted in partnership with INSERM, IntegraGen is setting up a biomarker validation programme that will make it possible to direct treatment of metastatic colorectal cancers using anti-EGFRs in a reliable and complete manner beyond the sole KRAS and BRAF mutations already known. The objective of the four-phase development process, carried out over a period of 36 months is to define a valid, integrated test that should become a patient-care standard prior to dispensing anti-EGFR treatment (colon cancer reference treatment).